ClexBio

ClexBio is a biotech company creating breakthrough solutions for tissue engineering and single-cell techniques by combining advanced microfluidics with our proprietary hydrogel technology CLEX. At ClexBio, we envision a world where no patient needs to die while waiting for an organ transplant, and where organ models can help to predict the effect of pharmaceuticals faster and more accurately to get them in the hands of suffering patients faster. The foundation of ClexBio is our fully-owned, proprietary hydrogel technology CLEX, is the result of more than 7 years of R&D within tissue engineering at NTNU, Harvard University, EPFL, and the University of Birmingham and has been published in internationally recognized scientific journals.